FLAIR-Only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival

Oncology (Switzerland)

Volumn 85, Issue 3, 2013, Pages 191-195

  Schaub, Christina ^a   Greschus, Susanne ^b   Seifert, Mirko ^b   Waha, Andreas ^b   Blasius, Elias ^a   Rasch, Katja ^a   Landwehr, Christiane ^a   Mack, Frederic ^a   Schäfer, Niklas ^a   Stuplich, Moritz ^a   Kebir, Sied ^a   Vilz, Belinda ^b   Scheffler, Björn ^a   Boström, Jan ^b   Simon, Matthias ^b   Urbach, Horst ^b,c   Glas, Martin ^a,b   Herrlinger, Ulrich ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b MediClin Robert Janker Klinik   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bevacizumab; Malignant glioma; MRI progression patterns

Indexed keywords

BEVACIZUMAB; IRINOTECAN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LOMUSTINE; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE; VINCRISTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE EXACERBATION; FEMALE; GLIOBLASTOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; CANCER PATIENT; CANCER REGRESSION; CHEMORADIOTHERAPY; DIFFUSION WEIGHTED IMAGING; FLUID ATTENUATION INVERSION RECOVERY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS;

ADULT; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DISEASE PROGRESSION; FEMALE; GERMANY; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84885632271     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000354692     Document Type: Article

References (14)

1. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729
2. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-1259
3. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740
4. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745
5. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 6624-6628
6. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY: An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009; 92: 149-155
7. Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W: Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011; 69: 586-592
8. Radbruch A, Lutz K, Wiestler B, Baumer P, Heiland S, Wick W, Bendszus M: Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol 2012; 14: 222-229
9. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Buttner R, Pietsch T, Waha A: Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 2007; 9: 368-381
10. Macdonald D, Cascino T, Schold SJ, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280
11. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972
12. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007; 25: 3357-3361
13. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779-787
14. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Coan AD, Herndon JE, Friedman HS: Bevacizumab (BV) continuation following BV progression: meta-analysis of five consecutive recurrent glioblastoma (GBM) trials (abstract). J Clin Oncol 2011; 29(suppl):2030